View ValuationUFP Technologies 将来の成長Future 基準チェック /16UFP Technologiesは、12.5%と6.2%でそれぞれ年率12.5%で利益と収益が成長すると予測される一方、EPSはgrowで10.6%年率。主要情報12.5%収益成長率10.58%EPS成長率Medical Equipment 収益成長13.3%収益成長率6.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日20 Jul 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBuy Or Sell Opportunity • Jul 23Now 20% undervaluedOver the last 90 days, the stock has risen 23% to €207. The fair value is estimated to be €259, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Significant insider selling over the past 3 months (€542k sold).お知らせ • Jun 29UFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic IndexUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Indexお知らせ • Jun 11Ufp Technologies, Inc. Announces Appointment of Mitchell C. Rock to the Board, Effective June 4, 2026UFP Technologies, Inc. announced that on June 4, 2026, the Board appointed Mitchell C. Rock to fill the vacancy on the Board created by such increase in Board size. Mr. Rock will serve on the Board until the Company’s next annual stockholder meeting or until his successor has been duly appointed and qualified or until his earlier death, resignation, retirement, disqualification, removal from office or other cause.お知らせ • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.お知らせ • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Recent Insider Transactions • May 20Lead Independent Director recently sold €542k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly €189 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.4m more than they bought in the last 12 months.お知らせ • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.お知らせ • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026お知らせ • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026お知らせ • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.お知らせ • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025お知らせ • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025お知らせ • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.お知らせ • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.お知らせ • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025お知らせ • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025Recent Insider Transactions • Nov 14CEO & Chairman recently sold €8.3m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly €327 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €13m. R. has been a net seller over the last 12 months, reducing personal holdings by €49m.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €321, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 435% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €144 per share.Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: US$2.13 (vs US$1.53 in 3Q 2023)Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold €3.6m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly €278 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by €3.7m.Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: US$1.77 (vs US$1.56 in 2Q 2023)Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.Reported Earnings • May 02First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.28 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €206, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 390% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €294 per share.Recent Insider Transactions • Mar 03CEO & Chairman recently sold €5.2m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly €194 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €19m.Reported Earnings • Feb 22Full year 2023 earnings released: EPS: US$5.89 (vs US$5.53 in FY 2022)Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.お知らせ • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold €3.3m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly €164 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €11m.Recent Insider Transactions • Dec 06Chairman of the Board of Directors recently sold €1.2m worth of stockOn the 30th of November, R. Bailly sold around 7k shares on-market at roughly €158 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.9m. R. has been a net seller over the last 12 months, reducing personal holdings by €7.3m.Recent Insider Transactions • Nov 27Chairman of the Board of Directors recently sold €208k worth of stockOn the 21st of November, R. Bailly sold around 1k shares on-market at roughly €160 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.7m. R. has been a net seller over the last 12 months, reducing personal holdings by €3.2m.Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$1.53 (vs US$2.58 in 3Q 2022)Third quarter 2023 results: EPS: US$1.53 (down from US$2.58 in 3Q 2022). Revenue: US$100.8m (up 3.9% from 3Q 2022). Net income: US$11.7m (down 40% from 3Q 2022). Profit margin: 12% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.Recent Insider Transactions • Sep 03Chairman of the Board of Directors recently sold €2.7m worth of stockOn the 31st of August, R. Bailly sold around 17k shares on-market at roughly €163 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €12m.Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$1.56 (vs US$1.18 in 2Q 2022)Second quarter 2023 results: EPS: US$1.56 (up from US$1.18 in 2Q 2022). Revenue: US$100.0m (up 6.0% from 2Q 2022). Net income: US$11.9m (up 33% from 2Q 2022). Profit margin: 12% (up from 9.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.Recent Insider Transactions • May 10Independent Director recently sold €3.4m worth of stockOn the 8th of May, Thomas Oberdorf sold around 27k shares on-market at roughly €129 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Cynthia Feldmann was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €120, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 102% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €85.63 per share.Reported Earnings • Mar 12Full year 2022 earnings released: EPS: US$5.53 (vs US$2.11 in FY 2021)Full year 2022 results: EPS: US$5.53 (up from US$2.11 in FY 2021). Revenue: US$353.8m (up 72% from FY 2021). Net income: US$41.8m (up 163% from FY 2021). Profit margin: 12% (up from 7.7% in FY 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.業績と収益の成長予測DB:UFP - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202872598N/AN/A112/31/202767985N/A95412/31/202664075N/A8643/31/2026609696981N/A12/31/2025603687992N/A9/30/2025598678799N/A6/30/2025589677383N/A3/31/2025548635970N/A12/31/2024504595767N/A9/30/2024462544555N/A6/30/2024417504353N/A3/31/2024407484050N/A12/31/2023400453141N/A9/30/2023390423647N/A6/30/2023386501828N/A3/31/202338047923N/A12/31/202235442418N/A9/30/202231937-110N/A6/30/202227321-64N/A3/31/20222291718N/A12/31/202120616914N/A9/30/2021195171622N/A6/30/2021188161924N/A3/31/2021180141924N/A12/31/2020179132125N/A9/30/2020184152126N/A6/30/2020191182430N/A3/31/2020199202732N/A12/31/201919820N/A31N/A9/30/201919918N/A30N/A6/30/201919717N/A26N/A3/31/201919516N/A27N/A12/31/201819014N/A21N/A9/30/201817713N/A18N/A6/30/201816510N/A17N/A3/31/20181549N/A11N/A12/31/20171489N/A17N/A9/30/20171478N/A16N/A6/30/20171499N/A16N/A3/31/20171499N/A16N/A12/31/20161468N/A9N/A9/30/20161448N/A10N/A6/30/20161417N/A9N/A3/31/20161397N/A12N/A12/31/20151398N/A13N/A9/30/20151407N/A14N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: UFPの予測収益成長率 (年間12.5% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: UFPの収益 ( 12.5% ) German市場 ( 15.8% ) よりも低い成長が予測されています。高成長収益: UFPの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: UFPの収益 ( 6.2% ) German市場 ( 6.7% ) よりも低い成長が予測されています。高い収益成長: UFPの収益 ( 6.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: UFPの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/27 14:33終値2026/07/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋UFP Technologies, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Jonathan TanwantengCJS Securities, Inc.Justin AgesCJS Securities, Inc.Brett FishbinKeyBanc Capital Markets Inc.4 その他のアナリストを表示
Buy Or Sell Opportunity • Jul 23Now 20% undervaluedOver the last 90 days, the stock has risen 23% to €207. The fair value is estimated to be €259, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 13% in 2 years. Earnings are forecast to grow by 29% in the next 2 years.
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Significant insider selling over the past 3 months (€542k sold).
お知らせ • Jun 29UFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic IndexUFP Technologies, Inc.(NasdaqCM:UFPT) dropped from Russell 2000 Dynamic Index
お知らせ • Jun 11Ufp Technologies, Inc. Announces Appointment of Mitchell C. Rock to the Board, Effective June 4, 2026UFP Technologies, Inc. announced that on June 4, 2026, the Board appointed Mitchell C. Rock to fill the vacancy on the Board created by such increase in Board size. Mr. Rock will serve on the Board until the Company’s next annual stockholder meeting or until his successor has been duly appointed and qualified or until his earlier death, resignation, retirement, disqualification, removal from office or other cause.
お知らせ • Jun 05UFP Technologies, Inc. Announces Appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, Effective June 4, 2026UFP Technologies, Inc. announced the appointment of Ryan Stafford as General Counsel and Senior Vice President of Human Resources, effective June 4, 2026. Stafford succeeded Chris Litterio, who retired after having played a pivotal role in the company’s growth. Stafford brought nearly three decades of experience as a senior legal and human resources leader at high-growth, publicly traded companies, leading Legal and Human Resources and overseeing M&A as well as helping guide corporate growth through both acquisition execution and organizational development. Most recently, Stafford served as Executive Vice President, Chief Legal Officer, Corporate Secretary, and head of Mergers & Acquisitions at Littelfuse, Inc. He joined Littelfuse in 2007 as General Counsel and Vice President of Human Resources, later advancing to Senior Vice President and Chief Legal and Human Resources from 2014 to 2021. In 2021, he was named Executive Vice President, Mergers & Acquisitions and Chief Legal Officer, where he led the company’s acquisition strategy. Prior to Littelfuse, Stafford held senior legal and operational roles at Tyco International Ltd., including Vice President & General Counsel for Tyco Engineered Products & Services and Vice President of China Operations for the segment. He began his legal career as an associate at Sulloway & Hollis, a New Hampshire law firm. Stafford earned a Bachelor of Arts in History and German from Bowdoin College and a Juris Doctor from the University of Maine School of Law.
お知らせ • May 27UFP Technologies, Inc. Announces Retirement of Christopher P. Litterio from General Counsel, Secretary, and Senior Vice President of Human ResourcesUFP Technologies, Inc. announced that on May 19, 2026, Christopher P. Litterio, General Counsel, Secretary, and Senior Vice President of Human Resources, informed the company that he planned to retire from the company after a period of transition.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Independent Director John Hassett was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Recent Insider Transactions • May 20Lead Independent Director recently sold €542k worth of stockOn the 12th of May, Daniel Croteau sold around 3k shares on-market at roughly €189 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.4m more than they bought in the last 12 months.
お知らせ • May 04UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026UFP Technologies, Inc., Annual General Meeting, Jun 04, 2026.
お知らせ • May 01UFP Technologies, Inc. to Report Q1, 2026 Results on May 04, 2026UFP Technologies, Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 04, 2026
お知らせ • Feb 20UFP Technologies, Inc. to Report Q4, 2025 Results on Feb 24, 2026UFP Technologies, Inc. announced that they will report Q4, 2025 results After-Market on Feb 24, 2026
お知らせ • Dec 03+ 1 more updateUFP Technologies, Inc. Technologies Announces Board ChangesUFP Technologies, Inc. announced that R. Jeffrey Bailly will retire as CEO at the Company’s next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will join the Company’s Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. Mr. Bailly intends to remain on the Board of Directors of the Company (the Board"). Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company's Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company's Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company's Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.
お知らせ • Oct 29UFP Technologies, Inc. to Report Q3, 2025 Results on Nov 03, 2025UFP Technologies, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025
お知らせ • Jul 30UFP Technologies, Inc. to Report Q2, 2025 Results on Aug 04, 2025UFP Technologies, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025
お知らせ • Jul 17UFP Technologies, Inc. (NasdaqCM:UFPT) acquired Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into securities purchase agreement to acquire Techno Plastics Industries, Inc. from a group of shareholders for $4.5 million on July 7, 2025. A cash consideration of $4.5 million will be paid by UFP Technologies, Inc. towards common equity of Techno Plastics Industries, Inc. The transaction were financed with available cash and borrowings under UFP’s existing credit facility. For the period ending December 31, 2024, Techno Plastics Industries, Inc. reported total revenue of approximately $10 million and EBITDA of $1 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Techno Plastics Industries, Inc. from a group of shareholders on July 17, 2025.
お知らせ • May 01UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025UFP Technologies, Inc., Annual General Meeting, Jun 04, 2025.
お知らせ • Apr 30UFP Technologies, Inc. to Report Q1, 2025 Results on May 06, 2025UFP Technologies, Inc. announced that they will report Q1, 2025 results Pre-Market on May 06, 2025
お知らせ • Feb 19UFP Technologies, Inc. to Report Q4, 2024 Results on Feb 25, 2025UFP Technologies, Inc. announced that they will report Q4, 2024 results on Feb 25, 2025
Recent Insider Transactions • Nov 14CEO & Chairman recently sold €8.3m worth of stockOn the 11th of November, R. Bailly sold around 25k shares on-market at roughly €327 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €13m. R. has been a net seller over the last 12 months, reducing personal holdings by €49m.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 27%After last week's 27% share price gain to €321, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total returns to shareholders of 435% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €144 per share.
Reported Earnings • Nov 05Third quarter 2024 earnings released: EPS: US$2.13 (vs US$1.53 in 3Q 2023)Third quarter 2024 results: EPS: US$2.13 (up from US$1.53 in 3Q 2023). Revenue: US$145.2m (up 44% from 3Q 2023). Net income: US$16.4m (up 40% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 27UFP Technologies, Inc. (NasdaqCM:UFPT) acquired AQF Ltd for €43 million.UFP Technologies, Inc. (NasdaqCM:UFPT) entered into a share purchase agreement to acquire AQF Ltd for €43 million on August 23, 2024. The shares were acquired for an aggregate purchase price of €43.0 million in cash. The aggregate purchase price at closing was approximately 12.3 times AQF Medical’s adjusted net income before interest, taxes, depreciation and amortization for the 12-month period ended June 30, 2024. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of AQF Ltd on August 26, 2024.
Recent Insider Transactions • Aug 08CFO, Senior VP & Treasurer recently sold €3.6m worth of stockOn the 6th of August, Ronald Lataille sold around 13k shares on-market at roughly €278 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Ronald has been a net seller over the last 12 months, reducing personal holdings by €3.7m.
Reported Earnings • Aug 01Second quarter 2024 earnings released: EPS: US$1.77 (vs US$1.56 in 2Q 2023)Second quarter 2024 results: EPS: US$1.77 (up from US$1.56 in 2Q 2023). Revenue: US$110.2m (up 10% from 2Q 2023). Net income: US$13.6m (up 14% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jul 17+ 1 more updateUFP Technologies, Inc. (NasdaqCM:UFPT) acquired Marble Medical Inc. for $5 million from Joseph J. Audie.UFP Technologies, Inc. (NasdaqCM:UFPT) signed a Stock Purchase Agreement to acquire Marble Medical Inc. for $5 million from Joseph J. Audie on June 24, 2024. The Marble shares were acquired for an aggregate purchase price of $4.5 million in cash plus up to an additional $0.5 million based upon the achievement of sales targets of Marble for each of the 12-month periods ended December 31, 2024 and 2025. In a related transaction UFP Technologies, Inc. acquired Welch Fluorocarbon. The aggregate purchase price at closing was approximately 4.5 times the Marble adjusted EBITDA. Marble Medical Inc. has annual sales of approximately $5 million. UFP Technologies, Inc. (NasdaqCM:UFPT) completed the acquisition of Marble Medical Inc. for $5 million from Joseph J. Audie on July 16, 2024.
Reported Earnings • May 02First quarter 2024 earnings released: EPS: US$1.66 (vs US$1.28 in 1Q 2023)First quarter 2024 results: EPS: US$1.66 (up from US$1.28 in 1Q 2023). Revenue: US$105.0m (up 7.4% from 1Q 2023). Net income: US$12.7m (up 30% from 1Q 2023). Profit margin: 12% (up from 10.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 2 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Apr 29UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024UFP Technologies, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 US Eastern Standard Time. Agenda: To elect the seven directors identified as standing for election in the accompanying proxy statement, each to serve until the 2025 Annual Meeting of Stockholders and until their successors are duly elected; to vote on a non binding advisory resolution to approve the compensation of named executive officers; to ratify the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ended December 31, 2024; and to transact such other business as may properly come before the 2024 Annual Meeting of Stockholders, and at any adjournment or postponement thereof.
Valuation Update With 7 Day Price Move • Mar 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €206, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Medical Equipment industry in Germany. Total returns to shareholders of 390% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €294 per share.
Recent Insider Transactions • Mar 03CEO & Chairman recently sold €5.2m worth of stockOn the 23rd of February, R. Bailly sold around 27k shares on-market at roughly €194 per share. This transaction amounted to 9.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €19m.
Reported Earnings • Feb 22Full year 2023 earnings released: EPS: US$5.89 (vs US$5.53 in FY 2022)Full year 2023 results: EPS: US$5.89 (up from US$5.53 in FY 2022). Revenue: US$400.1m (up 13% from FY 2022). Net income: US$44.9m (up 7.5% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Feb 06UFP Technologies, Inc. Announces Executive ChangesUFP Technologies, Inc. announced the appointment of Mitchell Rock as President of the Company. Rock has been serving as President of the Company’s MedTech business. R. Jeffrey Bailly will continue in his capacity as Chairman and Chief Executive Officer.
Recent Insider Transactions • Dec 18Chairman of the Board of Directors recently sold €3.3m worth of stockOn the 14th of December, R. Bailly sold around 20k shares on-market at roughly €164 per share. This transaction amounted to 6.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €11m.
Recent Insider Transactions • Dec 06Chairman of the Board of Directors recently sold €1.2m worth of stockOn the 30th of November, R. Bailly sold around 7k shares on-market at roughly €158 per share. This transaction amounted to 2.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.9m. R. has been a net seller over the last 12 months, reducing personal holdings by €7.3m.
Recent Insider Transactions • Nov 27Chairman of the Board of Directors recently sold €208k worth of stockOn the 21st of November, R. Bailly sold around 1k shares on-market at roughly €160 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €2.7m. R. has been a net seller over the last 12 months, reducing personal holdings by €3.2m.
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: US$1.53 (vs US$2.58 in 3Q 2022)Third quarter 2023 results: EPS: US$1.53 (down from US$2.58 in 3Q 2022). Revenue: US$100.8m (up 3.9% from 3Q 2022). Net income: US$11.7m (down 40% from 3Q 2022). Profit margin: 12% (down from 20% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
Recent Insider Transactions • Sep 03Chairman of the Board of Directors recently sold €2.7m worth of stockOn the 31st of August, R. Bailly sold around 17k shares on-market at roughly €163 per share. This transaction amounted to 4.5% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. R. has been a net seller over the last 12 months, reducing personal holdings by €12m.
Reported Earnings • Aug 02Second quarter 2023 earnings released: EPS: US$1.56 (vs US$1.18 in 2Q 2022)Second quarter 2023 results: EPS: US$1.56 (up from US$1.18 in 2Q 2022). Revenue: US$100.0m (up 6.0% from 2Q 2022). Net income: US$11.9m (up 33% from 2Q 2022). Profit margin: 12% (up from 9.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.
Recent Insider Transactions • May 10Independent Director recently sold €3.4m worth of stockOn the 8th of May, Thomas Oberdorf sold around 27k shares on-market at roughly €129 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €16m more than they bought in the last 12 months.
Board Change • Apr 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Director Cynthia Feldmann was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €120, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total returns to shareholders of 102% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €85.63 per share.
Reported Earnings • Mar 12Full year 2022 earnings released: EPS: US$5.53 (vs US$2.11 in FY 2021)Full year 2022 results: EPS: US$5.53 (up from US$2.11 in FY 2021). Revenue: US$353.8m (up 72% from FY 2021). Net income: US$41.8m (up 163% from FY 2021). Profit margin: 12% (up from 7.7% in FY 2021). Revenue is forecast to grow 4.1% p.a. on average during the next 2 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.